Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

This study found that the ALAVAX complex, containing 5-ALA and GHK peptide, may increase hair count in male pattern hair loss patients over 6 months without adverse events.

In this laboratory study, the methanolic extract of Eclipta alba demonstrated significant anthelmintic activity against earthworms (Pheretima posthuma), causing paralysis and death at doses of 50-100 mg/ml, with stronger effects observed at higher concentrations compared to the standard treatment, albendazole.

This study describes the molecular conformation and intermolecular interactions in the crystalline structure of the compound C24H31BrO4.

In this study, amitraz was found to be an effective and well-tolerated treatment for resolving sarcoptic mange in alpacas, demonstrating no relapse over a 10-month follow-up.

This study suggests that combining microneedling with ALA-photodynamic therapy may be a promising treatment option for moderate to severe alopecia areata, achieving significant hair regrowth in some patients.

This article discusses treatments for androgenic manifestations using cyproterone acetate alone or with estrogens, but it does not provide new clinical results.

This study found that a combination of topical and oral treatment led to greater improvements in hair density, thickness, and anagen/telogen ratio in patients with androgenetic alopecia compared to topical treatment alone, with significant benefits observed over a 3-month period.

This study found that inhibiting allopregnanolone synthesis in late gestation fetal sheep increased apoptosis and dead cell count in the hippocampus and cerebellum, effects that were mitigated by alfaxalone co-infusion.

This study found that altering Allopregnanolone levels in neonatal rats affects their adult exploratory and anxiety-like behaviors and impairs avoidance learning.

This study found that Eclipta alba extracts exhibit 5α-reductase inhibitory activity, with the methanolic extract showing a higher concentration of β-sitosterol compared to petroleum ether extract, indicating potential for treating androgenic conditions like male pattern baldness.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This article presents a collection of interdisciplinary studies by Brazilian researchers that address various societal issues to contribute to the nation's social and scientific development; it reports no new results.

This study investigated the integration of crystal engineering and microneedle technology for androgenetic alopecia treatment, finding that microneedles loaded with newly developed Kopexil multicomponent crystals reduced drug diffusion rates in vitro compared to standard formulations.

A new compound that could treat various androgen-related conditions was created and analyzed.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

This study reports the crystal structure and geometric parameters of a modified Finasteride derivative, highlighting significant differences in dihedral angles compared to its solvated analog and computational models.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.